Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI

Linghui Liang¹,², Feng Qi¹,², Yifei Cheng¹,², Lei Zhang³, Dongliang Cao¹, Gong Cheng¹* & Lixin Hua¹*

To analyze the clinical characteristics of patients with negative biparametric magnetic resonance imaging (bpMRI) who didn’t need prostate biopsies (PBs). A total of 1,012 male patients who underwent PBs in the First Affiliated Hospital of Nanjing Medical University from March 2018 to November 2019, of 225 had prebiopsy negative bpMRI (defined as Prostate Imaging Reporting and Data System (PI-RADS 2.1) score less than 3). The detection efficiency of clinically significant prostate cancer (CSPCa) was assessed according to age, digital rectal examination (DRE), prostate volume (PV) on bpMRI, prostate-specific antigen (PSA) and PSA density (PSAD). The definition of CSPCa for Gleason score > 6. Univariate and multivariable logistic regression analysis were used to identify predictive factors of absent CSPCa on PBs. Moreover, absent CSPCa contained clinically insignificant prostate cancer (CIPCa) and benign result. The detection rates of present prostate cancer (PCa) and CSPCa were 27.11% and 16.44%, respectively. Patients who were diagnosed as CSPCa had an older age (P < 0.001), suspicious DRE (P < 0.001), a smaller PV (P < 0.001), higher PSA value (P = 0.008) and higher PSAD (P < 0.001) compared to the CIPCa group and benign result group. PSAD < 0.15 ng/ml/cm³ (P = 0.004) and suspicious DRE (P < 0.001) were independent predictors of absent CSPCa on BPs. The negative forecast value of bpMRI for BP detection of CSPCa increased with decreasing PSAD, mainly in patients with naive PB (P < 0.001) but not in prior negative PB patients. 25.33% of the men had the combination of negative bpMRI, PSAD < 0.15 ng/ml/cm³ and PB naive, and none had CSPCa on repeat PBs. The incidence of PB was determined, CSPCa was 1.59%, 0% and 16.67% in patients with negative bpMRI, PSAD < 0.15 ng/ml/cm³ and biopsy naive and patients with negative bpMRI, PSAD < 0.15 ng/ml/cm³ and prior negative PB, separately. We found that a part of patients with negative bpMRI, a younger age, no suspicious DRE, significantly increased PSA value, a significantly small PV on MRI and PSAD > 0.15 ng/ml/cm³.

Multi-parametric magnetic resonance imaging (mpMRI) has marvelously sensitive power in detecting clinically significant prostate cancer (CSPCa). The function of mpMRI in prostate cancer (PCa) management has been continuously growing in the past decade¹. The current standard sequences are a combination of T2 weighted imaging (T2WI) plus two functional MRI sequences: Diffusion Weighted Imaging (DWI) and Dynamic Contrast Enhanced (DCE) imaging¹. Recent studies elaborated bi-parametric MRI (bpMRI) is a feasible implement with which to distinguish CSPCa. They recommended using supplemental implements to increase PCa detection in patients with Prostate Imaging Reporting and Data System (PI-RADS v2.1) ≥ 3¹. In addition, bpMRI has been displayed to have a diagnostic accuracy and PCa detection rate that are equivalent to those of mpMRI. BpMRI has the potential to result in substantial cost benefit and increased access to MRI in the diagnostic workflow and risk-stratification of men being evaluated for PCa when compared to conventional mpMRI¹. But there are still some debates about the interpretation of negative MRI. It is still controversial whether prostate biopsies (PBs) are necessary for patients without suspected index lesions on bpMRI. In this case, because there is no targeted

¹Department of Urology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, People’s Republic of China. ²These authors contributed equally: Linghui Liang, Feng Qi and Yifei Cheng. *email: gcheng@njmu.edu.cn; lixinhua@njmu.edu.cn
lesion, targeted biopsy is not applicable\(^6\). Repeat biopsies were usually needed to establish the diagnosis, but they can lead to over-detection and overtreatment of clinically insignificant prostate cancers (CIPCa), with a limited detection rate\(^7\). It has been implied that added negative predictors of CSPCa can help refine the decision making algorithm to more self-confidently determine whether patients with negative bpMRI need to undergo PBs\(^8\).

We analyzed the retrospective data of a group of patients with prebiopsy negative MRI in order to determine the factors that influence the detection rate of PCa or CSPCa, with which we can establish a low risk of significant disease in patients with negative MRI. Hence biopsy can be avoided in this group and further clinical decisions for this population can also be provided.

**Materials and methods**

**Study design and population.** We identified consecutive male patients who underwent prebiopsy bpMRI at our institution from March 2018 to November 2019. Patients were included in study if they had negative bpMRI, defined as PI-RADS v2.1 score less than 3\(^9\). During this period, 274 patients had prebiopsy negative bpMRI. Then we invited an experienced radiology doctor to reevaluate the MRI images of these patients. Forty-nine patients were excluded because they were reassessed as nonnegative MRI (Fig. 1). Finally, we analyzed 225 patients with negative MRI who met the inclusion criteria. All of the enrolled patients underwent systematic 14-core biopsy. All patients signed informed consent before conducting prostate biopsy. Rates of cancer detection were calculated from this group. CSPCa was defined as International Society of Urological Pathology (ISUP) grade 2 or higher based on histopathology findings, and scored as Gleason score (GS) 3 + 4 or higher\(^10\). This study was approved by the institutional review board and the First Affiliated Hospital of Nanjing Medical University Ethics Committee and informed consent was obtained from all patients and volunteers. We obey the principles of the 1983 Declaration of Helsinki. In other words, all of experiments in this paper obey this principle.

**BpMRI imaging protocol.** BpMRI Imaging was performed on a 3 T MRI system (Verio, Siemens, Erlangen, Germany). The MRI acquisition protocol included high resolution T2-weighted, diffusion-weighted and parametric apparent diffusion coefficient maps were calculated from the DWI\(^6\).

**BpMRI interpretation and demarcation of MRI suspicious lesion (mSL).** A single radiologist specializing in prostate imaging evaluated all examinations based on previously published prostate MRI interpretation and reporting methodology\(^11\). No mSLs were scored 1 or 2 and included in the evaluation\(^6\). If there are two suspicious lesions, PI-RADS takes the maximum value.
Biopsy procedure. Ultrasoundography system (HD11XE, Philips Ultrasound, Inc. 22100 Bothell Everett Highway Bothell, WA 98021–8421–8431, USA), head scanning probe, disposable biopsy gun and 18-G needles (MC1820, Bard Peripheral Vascular, Inc. 1625 West 3rd Street, Tempe, Arizona 85281, USA) were used for biopsies.

Transrectal ultrasound (TRUS) guided transrectal PB was performed by 5 experienced urologists with the patient without local anesthesia in operation room. Systematic extended sextant 12-core biopsies and 2-core biopsies.

Statistical analysis. We evaluated and updated our prostate MRI protocol which meets the recommendation of PI-RADS v2.1. Prostate volume (PV) was calculated using the ellipsoid formula based on MRI measurement12. All bpMRI were evaluated by an experienced radiologist with a minimum of 10 years of experience with prostate MRI.

To analyze data the patients were divided into 3 groups, including CSPCa, clinically significant prostate cancer (CIPCa) and benign groups. To assess predictors of absent CSPCa on PB patients were compared as CSPCa vs CIPCa group and benign group. Receiver Operating Characteristic (ROC) curve analysis was used to detect absent CSPCa on PB. Multivariable logistic regression analysis was done with clinically relevant parameters and statistically significant variables on univariate analysis8.

Data was analyzed using SPSS software (version 22.0, IBM Corp., Armonk, NY, USA) and GraphPad Prism 8 software (version 8.2.1, GraphPad, San Diego, CA, USA). The Mann–Whitney U test, the Kruskal–Wallis and post hoc tests were used for continuous variables and the chi-square or Fisher exact test was used for categorical variables. Statistical significance was defined as P < 0.05. We excluded patients with bpMRI done elsewhere and those who had undergone any prior surgical or medical treatment for PCa or BPH. And MRI should be done within 3 months before PB.

Results

Table 1 listed demographics. Of 208 (92.44%) patients were PB naive and 17 (7.56%) underwent previous negative PB. PB detected PCa in 61 men (27.11%) and CSPCa in 37 (16.44%).

Contrast among CSPCa, CIPCa and benign groups showed that prostate-specific antigen (PSA), age, PV, PSA density (PSAD) and suspicious digital rectal examination (DRE) were statistically different among these groups (P = 0.008, remaining P < 0.001, Table 1, Fig. 2).

Comparing 37 patients with CSPCa to 188 with absent CSPCa, univariate analysis showed that a younger age (P = 0.001), lower PSA value (P = 0.003), greater prostate volume (PV, P < 0.001), lower PSAD (P = 0.011), especially PSAD < 0.15 ng/ml/cm³ (P = 0.005) and suspicious DRE (P < 0.001) were predictors of detection of absent CSPCa in patients with negative MRI. Furthermore, multivariate analysis authenticated that a younger age (P = 0.001), greater PV (P < 0.001), lower PSAD (P = 0.011) and suspicious DRE (P = 0.006) were independent predictors of detection of absent CSPCa (Table 2). ROC curve analysis of absent CSPCa detection reveal a larger AUC for PSAD compared to PV or PSA or other parameters (0.8478 vs 0.8084 vs 0.6607, Fig. 3, Table 3).

All 57 patients (25.33%) with PSAD less than 0.15 ng/ml/cm³ and naive biopsy history had no CSPCa on biopsy. Conversely 36 of the 151 patients (23.84%) with PSAD ≥ 0.15 ng/ml/cm³ and naive biopsy had CSPCa on biopsy (Table 3). The negative predictive value (NPV) of bpMRI for CSPCa detection improved with decreasing PSAD (Table 3 and Fig. 4).

The NPV of negative bpMRI increased from 83.56% in all patients to 98.41% in patients with PSAD < 0.15 ng/ml/cm³. There was evidently improvement in the NPV of bpMRI in biopsy naive patients from...
Figure 2. Age and PSAD by PBx histology in patients with negative MRI.

Table 2. Predictors of absent PB detected, CSPCa in men with negative MRI. OR odds ratio, PSA prostate specific antigen, PV prostate volume on MRI, PSAD PSA density, DRE digital rectal examination.

| Parameter                      | Univariate                      | Multivariate            |
|--------------------------------|---------------------------------|-------------------------|
|                                | OR (95% CI)        | P value | OR (95% CI)    | P value |
| Age                            | 0.918 (0.872–0.966) | 0.001    | 0.902 (0.846–0.961) | 0.001 |
| PSA                            | 0.941 (0.903–0.979) | 0.003    | –                | – |
| PV                             | 1.088 (1.050–1.127) | < 0.001  | 1.083 (1.039–1.129) | < 0.001 |
| PSAD                           | 0.006 (0.001–0.045) | < 0.001  | 0.069 (0.009–0.547) | 0.011 |
| PSAD < 0.15 ng/ml/cm³          | 0.056 (0.008–0.421) | 0.005    | –                | – |
| DRE suspicious for PCa (yes or no) | 0.156 (0.070–0.347) | < 0.001  | 0.256 (0.098–0.672) | 0.006 |

Figure 3. ROC curve analysis of absent CSPCa in patients with negative MRI.
Both the high median PSAD of 0.26 ng/ml/cm³ and the fact that only 52% of patients underwent 3 T MRI with 1.5 T MRI performed in 49%.

Adding clinical information to mpMRI may help improve the NPV20,21. Washino et al. analyzed 288 patients who underwent biopsies, including 127 (44%) with negative MRI19. The multivariate analysis revealed that PI-RADS v2 score and PSAD were independent predictors for PCa and CSPCa. Biopsy naive patients were divided into 4 groups, including those with PSAD < 0.15, 0.15 to 0.29, 0.30 to 0.44 and 0.45 ng/ml/cm³ or greater, respectively. Finally, they concluded that biopsy should be recommended even after negative mpMRI and biopsy with saturation transperineal prostate biopsy as the reference standard18. 158 patients (27%) had negative mpMRI and NPV of CSPCa was 76%. But in this study, mpMRI was performed at 1.5 T strength and researchers did not assess predictors of absent CSPCa on biopsy in the case of negative MRI.

A retrospective study described that PCa and CSPCa diagnosis-free survival probabilities of 1,225 patients with negative mpMRI after 2 years of follow-up19. The 2-year PCa and CSPCa diagnosis-free survival rate were 84% and 95% in group A (659 biopsy naive patients) but in group B (596 prior negative biopsy patients) the rates were 96% and 96%, respectively. Finally, they concluded that biopsy should be recommended even after negative mpMRI, particularly young patients or patients with high or rising PSA19. These NPVs seem higher than those in our report. And the age of patients with MRI negative diagnosed with CSPCa is relatively large in our data.

In our single central study patients were brought into if there were no suspicious lesions on prebiopsy bpMRI as the reference standard18. 158 patients (27%) had negative mpMRI and NPV of CSPCa was 76%. But in this study, mpMRI was performed at 1.5 T strength and researchers did not assess predictors of absent CSPCa on biopsy in the case of negative MRI.

Table 3. MRI negative predictive value of CSPCa detection according to PSAD and PB history. PSAD PSA density.

| PSAD (ng/ml/cm³) | Overall | Biopsy Naive | Prior Neg Biopsy |
|-----------------|---------|--------------|-----------------|
| 0.15 or Greater | 36/162(77.78) | 36/151(76.16) | 0/11 (100.00) |
| Less than 0.15  | 1/63 (98.41) | 0/57(100.00) | 1/6 (83.33) |
| P value         | <0.001  | <0.001       | 0.353           |
| 0.15 or Greater | 36/162(77.78) | 36/151(76.16) | 0/11 (100.00) |
| 0.10-Less than 0.15 | 1/39 (97.44) | 0/35 (100.00) | 1/4 (75.00) |
| Less than 0.10  | 0/24 (100.00) | 0/22(100.00) | 0/2 (100.00) |
| P value         | <0.001  | <0.001       | 0.447           |

Table 3. MRI negative predictive value of CSPCa detection according to PSAD and PB history. PSAD PSA density.

Discussion

In our single central study patients were brought into if there were no suspicious lesions on prebiopsy bpMRI as the reference standard18. 158 patients (27%) had negative mpMRI and NPV of CSPCa was 76%. But in this study, mpMRI was performed at 1.5 T strength and researchers did not assess predictors of absent CSPCa on biopsy in the case of negative MRI.

A retrospective study described that PCa and CSPCa diagnosis-free survival probabilities of 1,225 patients with negative mpMRI after 2 years of follow-up19. The 2-year PCa and CSPCa diagnosis-free survival rate were 84% and 95% in group A (659 biopsy naive patients) but in group B (596 prior negative biopsy patients) the rates were 96% and 96%, respectively. Finally, they concluded that biopsy should be recommended even after negative mpMRI, particularly young patients or patients with high or rising PSA19. These NPVs seem higher than those in our report. And the age of patients with MRI negative diagnosed with CSPCa is relatively large in our data.

Adding clinical information to mpMRI may help improve the NPV20,21. Washino et al. analyzed 288 patients who underwent biopsies, including 127 (44%) with negative MRI19. The multivariate analysis revealed that PI-RADS v2 score and PSAD were independent predictors for PCa and CSPCa. Biopsy naive patients were divided into 4 groups, including those with PSAD < 0.15, 0.15 to 0.29, 0.30 to 0.44 and 0.45 ng/ml/cm³ or greater, respectively. Only 2 of the 51 patients with PSAD less than 0.15 ng/ml/cm³ had CSPCa. However, it is important to note the high median PSAD of 0.26 ng/ml/cm³ in this cohort and the fact that only 52% of patients underwent 3 T MRI with 1.5 T MRI performed in 49%.

Distler et al. biopsied 1040 patients who assessed MRI by PI-RADS v19. 344 of them (33%) had no suspicious lesions on mpMRI. Patients were stratified into 3 PSAD groups, including < 0.07, 0.07 to 0.15 and > 0.15 ng/ml/cm³ respectively. When combined with PSAD = 0.15 ng/ml/cm³ and PSAD = 0.15 ng/ml/cm³, the NPV of mpMRI for CSPCa increased from 79 to 89%. When combining PSAD and mpMRI, about 20% of the biopsies seem unnecessary.

We used PSAD and DRE suspicious for PCa, and excluded PV from multivariable analysis to avoid confounding factors. According to several reports and as recommended by NCCN Guidelines, we used a PSAD threshold of 0.15 ng/ml/cm³ for analysis13,20,22. According to research conclusions, the study of 285 cases of radical prostatectomy (RP) specimens showed that PSAD was better than PSA and GS in predicting positive surgical margins, extra capsular disease, lymph node invasion and seminal vesicle invasion23. By contrast, PSAD < 0.15 ng/ml/cm³ with less than 3 mm PCa found in only one positive core in biopsy were predictors of CIPCa in RP samples24.

In other negative MRI markers of patients, including PSAD, might replenish value in identifying those necessary repeat biopsy25. The recent analysis found that mpMRI should be considered in patients with previous negative biopsy who have suspicion for PCa and are being considered for repeat PB25. Patients with a history of prior negative biopsy have lower PCa detection rate on repeat biopsy. Ploussard et al. compared the data of 617 patients who underwent repeat biopsy with a mean of follow-up 19 months26. The researchers compared 16.7%,
16.9% and 12.5% PCa detection rates for the 2nd, 3rd and 4th sets of repeat biopsies, respectively. They found that PSAD > 0.15 ng/ml/cm³ more than doubled PCa detection on repeat biopsy, too.

Most interestingly, in our study, only 1 patient had CSPCa on repeat biopsy when combining negative MRI, PSAD < 0.15 ng/ml/cm³ and previous negative PB history.

However, patients with PSAD ≥ 0.15 ng/ml/cm³, suspicious DRE and naive PB history should undergo PB even if bpMRI doesn't show lesions (Table 1).

Figure 4. Negative predictive value of MRI for CSPCa. (a) by PSAD. (b) by PSAD and PBx and PBx status.
Our research was limited by a relatively small number of patients. The number of prior negative biopsies is relatively small compared to the number of naive biopsies. However, our group size is bigger than those in prior reports. The patients who underwent prior negative biopsies used different biopsy protocols with a varying number of cores taken, which were not available from reports done elsewhere. Nevertheless, we report the BMI of patients and further stratified analysis of PSAD but to our knowledge no prior publication has done so. According to PI-RADS criteria, good quality bpMRI were performed, interpreted and reported by experienced radiologists. And to reduce research errors, we asked our agency’s most experienced uroradiologists to reevaluate MRI reports rigorously. This detail was rarely seen in reports elsewhere.

Our study was a single-institute study. A major limitation of it was relatively small sample size. In addition, there was a potential selection bias to this retrospective study. Therefore, more prospective studies with a larger cohort of subjects were needed to support the present findings.

Our data reflected real practice. PBs were performed by well-experienced urologists, and histological results were reviewed by a specialized pathologist.

Conclusions
The NPV of bpMRI for CSPCa was 83.56%, which improved to 98.41% when combined with PSAD < 0.15 ng/ml/cm³. Patients with a combination of negative bpMRI and PSAD < 0.15 ng/ml/cm³ can securely avoid PB as only 1 patient with prior negative biopsy had CSPCa on PB. On the contrary, PB should be considered in patients regardless of negative bpMRI, particularly those with PSAD ≥ 0.15 ng/ml/cm³ and suspicious DRE.

Received: 6 August 2020; Accepted: 8 February 2021
Published online: 15 March 2021

References
1. Gortz, M. et al. The value of prostate-specific antigen density for prostate imaging-reporting and data system 3 lesions on multiparametric magnetic resonance imaging: a strategy to avoid unnecessary prostate biopsies. Eur. Urol. Focus https://doi.org/10.1016/j.euf.2019.11.012 (2019).
2. Mottet, N. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71, 618–629. https://doi.org/10.1016/j.eururo.2016.08.003 (2017).
3. Rosenkrantz, A. B. et al. Interobserver reproducibility of the PI-RADS version 2 lexicon: a multicenter study of six experienced prostate radiologists. Radiology 280, 793–804. https://doi.org/10.1148/radiol.2016152542 (2016).
4. Kim, Y. J.,Flüh, J. S. & Park, K. K. Effectiveness of bi-parametric MR-US fusion biopsy for detecting clinically significant prostate cancer in prostate biopsy Naïve men. Yonsei Med. J. 60, 346–351. https://doi.org/10.3339/ymj.2019.60.4.346 (2019).
5. Porter, K. K. et al. Financial implications of biparametric prostate MRI. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-019-0158-x (2019).
6. Wysock, J. S. et al. Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. BJU Int. 118, 515–520. https://doi.org/10.1111/bju.13427 (2016).
7. Ploussard, G. et al. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance—does the risk of misclassification vary according to biopsy criteria? J. Urol. 183, 539–544. https://doi.org/10.1016/j.juro.2009.10.009 (2010).
8. Oishi, M. et al. Which patients with negative magnetic resonance imaging can safely avoid biopsy for prostate cancer? J. Urol. 201, 268–276. https://doi.org/10.1016/j.juro.2018.08.046 (2019).
9. Weinreb, J. C. et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2. J. Urol. 201, 618–629. https://doi.org/10.1016/j.juro.2017.03.130 (2017).
10. Epstein, J. I., Walsh, P. C., Carmichael, M. & Brendler, C. B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer in prostate biopsy Naive men. BJU Int. 119, 225–233. https://doi.org/10.1111/bju.13465 (2017).
11. Lu, A. J. et al. Negative multiparametric magnetic resonance imaging of the prostate predicts absence of clinically significant prostate cancer on 12-core template prostate biopsy. Urology 105, 118–122. https://doi.org/10.1016/j.urology.2017.01.048 (2017).
12. Hansen, N. L. et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naive men with suspicion of prostate cancer. BJU Int. 122, 40–49. https://doi.org/10.1111/bju.14049 (2018).
13. Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822. https://doi.org/10.1016/S0140-6736(16)32401-1 (2017).
14.Panebianco, V. et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what’s next? Eur. Urol. 74, 48–54. https://doi.org/10.1016/j.eururo.2018.03.007 (2018).
15. Didler, F. A. et al. The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction. J. Urol. 198, 575–582. https://doi.org/10.1097/JURO.0000000000008150 (2017).
16. Drukin, S. C. et al. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int. 121, 619–626. https://doi.org/10.1111/bju.14098 (2018).
17. Carroll, P. H. & Mohler, J. L. NCCN guidelines updates: prostate cancer and prostate cancer early detection. J. Natl. Compr. Cancer Netw. 16, 620–623. https://doi.org/10.6004/jnccn.2018.0036 (2018).
18. Szourgariostos, S. & Perimenis, P. PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer. Can. Urol. Assoc. J. 6, 46–50. https://doi.org/10.5489/cuaj.11079 (2012).
19. Epstein, J. I., Walsh, P. C., Carmichael, M. & Brendler, C. B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271, 368–374 (1994).
25. Rosenkrantz, A. B. et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J. Urol. 196, 1613–1618. https://doi.org/10.1016/j.juro.2016.06.079 (2016).

Acknowledgements
We thanked the pathologists (Meiling Bao) and radiologists (Yudong Zhang, et al.) in the department of pathology and radiology in the first affiliated hospital with Nanjing Medical University for their help.

Author contributions
Conception and design: L.H. and G.C., Development of methodology: L.L., F.Q., and Acquisition of data (acquired and managed patients, provided facilities, etc.): F.Q., Y.C., D.C. and L.Z. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L.L., F.Q. Writing, review, and/or revision of the manuscript: L.L., F.Q. Study supervision and guarantors: L.H.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to G.C. or L.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021